Eric Dansin
Eric Dansin is an expert in Oncology at Centre Oscar Lambret (France). As of January 2026, ScienceLeadR ranks Eric Dansin in the top 1% of experts worldwide for Thoracic Neoplasms. Eric Dansin has authored 230 publications, the most recent in 2025, and is an investigator in 22 clinical trials, 1 of them ongoing. SLR score: 648 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Endocrinology - Public Health - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1991 - 2025
Number : 230
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy. PMID 41275528 — neoplasms, carcinoma, non-small-cell lung, immunotherapy, therapeutics | Eur J Cancer | 2025 | 0 |
| Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. PMID 40907517 — thymoma, progression-free survival, neoplasms, drug therapy, drug-related side effects and adverse reactions, therapeutics, chemotherapy | Lancet Oncol Top journal | 2025 | 1 |
| Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis. PMID 40706224 — lung, smokers, neoplasms, propensity score, drug therapy, immunotherapy, lung neoplasms, therapeutics, chemotherapy | ESMO Open | 2025 | 5 |
| Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. PMID 38913539 — somatostatin, paraneoplastic endocrine syndromes, therapeutics, carcinoid tumor, endocrine system diseases | Endocr Relat Cancer | 2024 | 10 |
| Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort. PMID 38833966 — lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, therapeutics, mutation, prognosis | ESMO Open | 2024 | 4 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Analysis of Biological Characteristics of Advanced ALK rearranged NSCLC NCT05122806 — cells, genes, lung, blood, neoplasms, disease progression, base sequence, gene rearrangement, carcinoma, non-small-cell lung, biopsy, lung neoplasms, small cell lung carcinoma, diagnosis, tissues, dna, mutation, carcinoma | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map